Previous 10 | Next 10 |
NovoCure Limited (NVCR) is expected to report $-0.51 for Q3 2023
2023-10-25 14:02:09 ET More on NovoCure NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade) NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth HC Wainwright cuts NovoC...
2023-10-18 10:31:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The third quarter was ...
Highlights include a new analysis showing that Tumor Treating Fields therapy, when added to standard systemic therapies, did not adversely affect patients’ quality of life in the phase 3 LUNAR clinical trial. Novocure (NASDAQ: NVCR) today announced its participation in the Eu...
Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the thr...
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTField...
2023-09-19 10:15:00 ET Young medical companies with new therapies often navigate a challenging path. That's true today for NovoCure (NASDAQ: NVCR) , which makes a wearable device for treating cancer. The average investor might see NovoCure as yet another struggling cancer therapy co...
Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Ca...
2023-09-06 14:27:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regard...
News, Short Squeeze, Breakout and More Instantly...
NovoCure Limited Company Name:
NVCR Stock Symbol:
NASDAQ Market:
2024-06-13 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 10:45:03 ET Wells Fargo analyst issues NEUTRAL recommendation for NVCR on June 4, 2024 09:01AM ET. The previous analyst recommendation was Neutral. NVCR was trading at $24.055 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients treated with supportive care alone Patients treated with TTFields therapy experienced prolonged quality of l...